Inclusion Criteria:

- Patients must have histologically confirmed malignancy that is metastatic or
unresectable and for which standard curative or palliative measures do not exist or
are no longer effective; patients with solid hematologic malignancies (Hodgkin's and
non-Hodgkin's lymphomas) may be included as long as a bone marrow has been performed
within 6 weeks of enrollment

- Prior chemotherapy is allowed; patients may not have received chemotherapy for 4
weeks prior to the initiation of study treatment and must have full recovery from the
acute effects of any prior chemotherapy; patients must not have had nitrosoureas or
mitomycin C for 6 weeks prior to initiation of study treatment

- Prior radiation therapy is allowed; patients must have completed radiation at least 4
weeks prior to initiation of study treatment; patients who have received prior
radiation to 50% or more of their total marrow volume will be excluded

- Prior treatment with EGFR inhibitors is allowed; prior experimental therapies (non
FDA-approved agents) and immunotherapies are allowed; patients may not have received
these therapies for 4 weeks prior to the initiation of study treatment and must have
a full recovery from the acute effects of these therapies

- ECOG performance status =< 2 (Karnofsky >= 60%)

- Life expectancy of > 12 weeks

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Total bilirubin =< normal institutional limits

- AST(SGOT)/ALT(SGPT) =< 2.5 X institutional upper limit of normal

- Creatinine =< 1.5 X institutional upper limit of normal OR creatinine clearance
(calculated) or measured clearance >= 60 mL/min/1.73 m^2 for patients with creatinine
levels above institutional normal

- The effects of SB-715992 on the developing human fetus are unknown; for this reason
and because mitotic inhibitors are known to be teratogenic, women of child-bearing
potential and men must agree to use adequate contraception (hormonal or barrier
method of birth control; abstinence) prior to study entry and for the duration of
study participation; should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from acute AEs due to agents administered more than 4 weeks earlier

- Patients may not have received any other investigational agents within 28 days of
study entry

- Patients may not receive any other anti-cancer therapy (cytotoxic, biologic,
radiation, or hormonal other than for replacement) while on this study except for
medications that are prescribed for supportive care but potentially may have
anticancer effect (i.e. megestrol acetate, bisphosphonates); these medications must
have been started 1 month prior to enrollment on study; in addition, men receiving
treatment for prostate cancer will be maintained at castrate levels of testosterone
by continuation of luteinizing- releasing hormone agonists

- Prohibited medications: SB-715992 is a moderate to significant in vitro inhibitor of
CYP3A4; the following lists of medications/substances are moderate to significant
inhibitors/inducers of CYP3A4 that, if administered concomitantly with SB-715992, may
alter study drug exposure; the use of these medications/substances within 14 days (>=
6 months for amiodarone) prior to the administration of the first dose of SB-715992
through discontinuation from the study is prohibited;

- Inhibitors of CYP3A4

- Antibiotics: clarithromycin, erythromycin, troleandomycin

- Antifungals: itraconazole, ketoconazole, fluconazole (doses > 200 mg/day),
voriconazole

- Antidepressants: nefazodone, fluovoxamine

- Calcium channel blockers: verapamil, diltiazem

- Bitter Orange

- Miscellaneous: amiodarone*, grapefruit juice**; *use of amiodarone within 6
months prior to the administration of the first dose of SB-715992 is
prohibited; ** use of grapefruit juice within 7 days prior to
administration of the first dose of SB-715992 is prohibited

- Inducers of CYP3A4

- Anticonvulsants: phenytoin, carbamazepine, phenobarbital

- Antibiotics: rifampin, rifabutin, rifapentine

- Miscellaneous: St. John's wort, modafinil, oxcarbazepine

- Patients with known, symptomatic or untreated brain metastases should be excluded
from this clinical trial because of their poor prognosis and because they often
develop progressive neurologic dysfunction that would confound the evaluation of
neurologic and other adverse events

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study because SB-715992 is a mitotic inhibitor
with the potential for teratogenic or abortifacient effects; because there is an
unknown but potential risk for adverse events in nursing infants secondary to
treatment of the mother with SB-715992, breastfeeding should be discontinued if the
mother is treated with SB-715992

- Patients with immune deficiency are at increased risk of lethal infections when
treated with marrow-suppressive therapy; therefore, HIV-positive patients receiving
combination anti-retroviral therapy are excluded from the study because of possible
pharmacokinetic interactions with SB-715992; appropriate studies will be undertaken
in patients receiving combination anti-retroviral therapy when indicated

- Patients are ineligible for participation in the Drug Interaction study, or can be
deemed to be ineligible to receive certain drug probes, if they have:

- Sensitivity to sulfa drugs or adverse reactions to sulfonylureas

- Concurrent antifungal medications, or within the past 4 weeks

- Diabetes or other glucose imbalance

- Acidosis

- Concurrent alcohol use (based on the discretion of treating physician)

- Concurrent phenytoin or diazepam treatment, or within the past 4 weeks

- Previous intolerance to benzodiazepam therapies

- A patient maybe excluded from all or a portion of the Drug Interaction study
based on the medical discretion of the investigator

- EVEN THOUGH PATIENTS MAY BE INELIGIBLE TO PARTICIPATE IN THE DRUG INTERACTION
STUDY, THEY CAN STILL PARTICIPATE IN THE PHASE I CLINICAL TRIAL